{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:11Z","timestamp":1790742011945,"version":"4.1.0"},"reference-count":83,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2018,7,4]]},"DOI":"10.1080\/09546634.2017.1395806","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T09:57:31Z","timestamp":1509703051000},"page":"441-449","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":60,"title":["Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials"],"prefix":"10.1080","volume":"29","author":[{"given":"Melody","family":"Maarouf","sequence":"first","affiliation":[{"name":"College of Medicine, University of Arizona, Tucson, AZ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley K.","family":"Clark","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, Davis, Sacramento, CA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan E.","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology, University of Arizona, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S111019"},{"key":"CIT0002","volume-title":"Fitzpatrick\u2019s color atlas and synopsis of clinical dermatology","author":"Wolff K","year":"2017","edition":"8"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.016"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.067"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14517"},{"key":"CIT0006","first-page":"46","volume":"152","author":"Shalom G.","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13777"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12068"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15424"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903907"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00714.x"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030896"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01552.x"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2016.1230867"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.315"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3908061"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2450401"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.036"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.026"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.8.1631.1631"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.3109\/09546630902936778"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13233"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.110753"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4097574"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0516-5"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.017"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"CIT0033","unstructured":"AbbVie. Humira (adalimumab) [Internet]. 2001. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s0110lbl.pdf."},{"key":"CIT0034","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01468207. Efficacy and safety study of adalimumab in treatment of hidradenitis suppurativa (PIONEER I). 2011. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01468207?cond=Efficacy+and+Safety+ Study+of+Adalimumab+in+Treatment+of+Hidradenitis+Suppurativa&rank =1."},{"key":"CIT0035","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01468233. Efficacy and safety study of adalimumab in the treatment of hidradenitis suppurativa (PIONEER II). 2011. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01468233?cond=Efficacy+and+Safe-ty+Study+of+Adalimumab+in+Treatment+of+Hidradenitis+Suppurativa&rank =2."},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"CIT0037","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01635764. Open-label study of the safety and efficacy of adalimumab in the treatment of hidradenitis suppurativa. 2012. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01635764."},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.146"},{"key":"CIT0039","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02904902. Open-label study of adalimumab in Japanese subjects with hidradenitis suppurativa. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02904902."},{"key":"CIT0040","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02808975. Safety and efficacy of humira (adalimumab) for hidradenitis suppurativa (HS) peri-surgically (SHARPS study). 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808975."},{"key":"CIT0041","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03001115. Post-marketing surveillance of adalimumab in Korean hidradenitis suppurativa subjects. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03001115."},{"key":"CIT0042","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02896920. Canadian humira post marketing observational epidemiological study: assessing humira real-life effectiveness and impact on HS burden of illness. 206. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02896920."},{"key":"CIT0043","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02739828. Post marketing observational study (PMOS) to assess quality of life in Swedish hidradenitis suppurativa (HS) Patients. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02739828."},{"key":"CIT0044","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02786576. Effectiveness of adalimumab in moderate to severe hidradenitis suppurativa patients \u2013 a multi country study in real life setting. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02786576."},{"key":"CIT0045","unstructured":"Amgen. Enbrel (etanercept) [Internet]. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf."},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.7.1137"},{"key":"CIT0047","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00108991. Etanercept for treatment of hidradenitis. 2005. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00107991."},{"key":"CIT0048","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00949546. Treatment of hidradenitis suppurativa using etanercept. 2009. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00949546."},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.72"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.898"},{"key":"CIT0051","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00329823. Etanercept in hidradenitis suppurativa. 2006. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00329823."},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07067.x"},{"key":"CIT0053","unstructured":"Janssen Biotech. Remicade (infliximab) [Internet]. 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf."},{"key":"CIT0054","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00795574. Study to assess the safety and efficacy of infliximab to treat hidradenitis suppurtativa. 2008. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00795574."},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.050"},{"key":"CIT0056","unstructured":"Swedish Orphan Biovitrum AB. Kineret (anakinra) [Internet]. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf."},{"key":"CIT0057","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01516749. Anakinra as a treatment for hydradenitis suppurativa. 2012. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01516749."},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903"},{"key":"CIT0059","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01558375. Anakinra in hidradenitis suppurativa. 2012. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01558375."},{"key":"CIT0060","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01838499. Assessment of the safety, tolerability and efficacy of MEDI8968 in subjects with moderate to severe hidradenitis suppurativa. 2013. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01838499."},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1269580"},{"key":"CIT0062","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02643654. MABp1 in hidradenitis suppurativa refractory to adalimumab. 2015. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02643654."},{"key":"CIT0063","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02421172. Efficacy, safety, and pharmacokinetics study of CJM112 in hidradenitis suppurativa patients. 2015. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421172."},{"key":"CIT0064","unstructured":"Novartis Pharma AG. Cosentyx (secukinumab) [Internet]. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125504s001s002lbl.pdf."},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15769"},{"key":"CIT0066","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03099980. Exploratory trial evaluating cosentyx (secukinumab) for patients with moderate-to-severe hidradenitis suppurativa. 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03099980."},{"key":"CIT0067","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03248531. A study to test the efficacy, safety and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativa. 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03248531."},{"key":"CIT0068","unstructured":"Janssen Biotech. Stelara (ustekinumab) [Internet]. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf."},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04123.x"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14338"},{"key":"CIT0071","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01704534. A proof of concept study to evaluate the effectiveness of ustekinumab in hidradenitis suppurativa. 2012. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01704534."},{"key":"CIT0072","unstructured":"Celgene Corporation. Otezla (apremilast) [Internet]. 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206088s000lbl.pdf."},{"key":"CIT0073","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03049267. Short-term safety, efficacy and mode of action of apremilast in moderate suppurative hidradenitis. 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03049267."},{"key":"CIT0074","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02695212. Single center study of apremilast for the treatment of hidradenitis suppurativa. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02695212."},{"key":"CIT0075","unstructured":"Genentech. RAPTIVA [efalizumab] [Internet]. 2009. Available from: https:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm143346.pdf."},{"key":"CIT0076","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00134134. Efficacy and safety of efalizumab in the treatment of moderate-severe hydradenitis auppurativa. 2005. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00134134."},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.032"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1080\/09546630902984596"},{"key":"CIT0079","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03001622. Studying complement inhibition in patients with moderate to severe hidradenitis suppurativa. 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03001622."},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.220"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.255"},{"key":"CIT0082","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00918255. Study of adalimumab in subjects with moderate to severe chronic hidradenitis suppurativa. 2009. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00918255."},{"key":"CIT0083","unstructured":"ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00827996. To assess the efficacy and safety of adalimumab in subjects with moderate to severe hidradenitis suppurativa. 2009. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00827996."}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2017.1395806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T14:17:36Z","timestamp":1661177856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2017.1395806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,7,4]]}},"alternative-id":["10.1080\/09546634.2017.1395806"],"URL":"https:\/\/doi.org\/10.1080\/09546634.2017.1395806","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}